Neuroprotective effect of GYKI 52466 on AMPA-induced neurotoxicity in rat striatum

E. Bartha, G. Lovas, E. Szentkuty, E. J. Horvath, M. Palkóvits

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The neuroprotective effect of intraperitonally administered GYKI 52466 (2,3-benzodiazepine derivate) was investigated on AMPA (alpha-amino-3- hydroxy-5-methyl-4-isoxalon-propionic acid)-induced neuronal degeneration in the striatum of adult rats. The dose-dependent neurotoxic effect of AMPA was evaluated by the decrease in the activity of choline acetyltransferase (CHAT), due to degeneration of cholinergic neurons. An injection of 25 mg/kg GYKI 52466 30 min prior to the striatal application of 50 nmol AMPA, followed by repeated application of GYKI 52466 (10 times 5 mg/kg at 10 min intervals, reaching a final dose of 75 mg/kg) was able to prevent neuronal damage monitored by ChAT activity. Conversely, co-injection of GYKI 52466 (50 and 75 mg/kg) with AMPA (50 and 100 nmol) did not elicit any significant protection against the neuronal loss as measured by the ChAT enzyme activity. Therefore, one dose of agonist decreasing ChAT activity by about 40% (50 nmol) was tested on [3H]girisopam binding sites and on the immunoreactivity of glial fibrillary acid protein. The lesions were measured on methylene blue-stained serial sections with a computer assisted image analysis program (NIH Image 1.60). As a result of the AMPA treatment [3H]girisopam binding sites became depleted, and the immunoreactivity of glial fibrillary acid protein increased and on the site of the injection in the striatum a lesion developed. In the presence of AMPA (50 nmol) administered intrastriatally, GYKI 52466 (75 mg/kg i.p.) was able to make the radioactive signal of [3H]girisopam reappear. The volume of AMPA induced neuronal damage in the striatum and the extent of gliosis was reduced. These data provide evidence for the neuroprotective effect of GYKI 52466, and suggest a potential therapeutic value in some neurological disorders.

Original languageEnglish
Pages (from-to)127-139
Number of pages13
JournalNeurobiology
Volume6
Issue number2
Publication statusPublished - 1998

Fingerprint

alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
Neuroprotective Agents
Glial Fibrillary Acidic Protein
Injections
Binding Sites
Corpus Striatum
Cholinergic Neurons
Gliosis
Choline O-Acetyltransferase
Computer-Assisted Image Processing
Methylene Blue
GYKI 52466
Nervous System Diseases
Benzodiazepines
Enzymes
Therapeutics
girisopam

Keywords

  • AMPA,
  • ChAT
  • Girisopam
  • GYLI 52466
  • Image analysis
  • Neuroprotection
  • Striatum

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Bartha, E., Lovas, G., Szentkuty, E., Horvath, E. J., & Palkóvits, M. (1998). Neuroprotective effect of GYKI 52466 on AMPA-induced neurotoxicity in rat striatum. Neurobiology, 6(2), 127-139.

Neuroprotective effect of GYKI 52466 on AMPA-induced neurotoxicity in rat striatum. / Bartha, E.; Lovas, G.; Szentkuty, E.; Horvath, E. J.; Palkóvits, M.

In: Neurobiology, Vol. 6, No. 2, 1998, p. 127-139.

Research output: Contribution to journalArticle

Bartha, E, Lovas, G, Szentkuty, E, Horvath, EJ & Palkóvits, M 1998, 'Neuroprotective effect of GYKI 52466 on AMPA-induced neurotoxicity in rat striatum', Neurobiology, vol. 6, no. 2, pp. 127-139.
Bartha, E. ; Lovas, G. ; Szentkuty, E. ; Horvath, E. J. ; Palkóvits, M. / Neuroprotective effect of GYKI 52466 on AMPA-induced neurotoxicity in rat striatum. In: Neurobiology. 1998 ; Vol. 6, No. 2. pp. 127-139.
@article{40d5917618d54cccbe825e4a724a229f,
title = "Neuroprotective effect of GYKI 52466 on AMPA-induced neurotoxicity in rat striatum",
abstract = "The neuroprotective effect of intraperitonally administered GYKI 52466 (2,3-benzodiazepine derivate) was investigated on AMPA (alpha-amino-3- hydroxy-5-methyl-4-isoxalon-propionic acid)-induced neuronal degeneration in the striatum of adult rats. The dose-dependent neurotoxic effect of AMPA was evaluated by the decrease in the activity of choline acetyltransferase (CHAT), due to degeneration of cholinergic neurons. An injection of 25 mg/kg GYKI 52466 30 min prior to the striatal application of 50 nmol AMPA, followed by repeated application of GYKI 52466 (10 times 5 mg/kg at 10 min intervals, reaching a final dose of 75 mg/kg) was able to prevent neuronal damage monitored by ChAT activity. Conversely, co-injection of GYKI 52466 (50 and 75 mg/kg) with AMPA (50 and 100 nmol) did not elicit any significant protection against the neuronal loss as measured by the ChAT enzyme activity. Therefore, one dose of agonist decreasing ChAT activity by about 40{\%} (50 nmol) was tested on [3H]girisopam binding sites and on the immunoreactivity of glial fibrillary acid protein. The lesions were measured on methylene blue-stained serial sections with a computer assisted image analysis program (NIH Image 1.60). As a result of the AMPA treatment [3H]girisopam binding sites became depleted, and the immunoreactivity of glial fibrillary acid protein increased and on the site of the injection in the striatum a lesion developed. In the presence of AMPA (50 nmol) administered intrastriatally, GYKI 52466 (75 mg/kg i.p.) was able to make the radioactive signal of [3H]girisopam reappear. The volume of AMPA induced neuronal damage in the striatum and the extent of gliosis was reduced. These data provide evidence for the neuroprotective effect of GYKI 52466, and suggest a potential therapeutic value in some neurological disorders.",
keywords = "AMPA,, ChAT, Girisopam, GYLI 52466, Image analysis, Neuroprotection, Striatum",
author = "E. Bartha and G. Lovas and E. Szentkuty and Horvath, {E. J.} and M. Palk{\'o}vits",
year = "1998",
language = "English",
volume = "6",
pages = "127--139",
journal = "Ideggyogyaszati Szemle",
issn = "0019-1442",
publisher = "Ifjusagi Lap-es Konyvkiado Vallalat",
number = "2",

}

TY - JOUR

T1 - Neuroprotective effect of GYKI 52466 on AMPA-induced neurotoxicity in rat striatum

AU - Bartha, E.

AU - Lovas, G.

AU - Szentkuty, E.

AU - Horvath, E. J.

AU - Palkóvits, M.

PY - 1998

Y1 - 1998

N2 - The neuroprotective effect of intraperitonally administered GYKI 52466 (2,3-benzodiazepine derivate) was investigated on AMPA (alpha-amino-3- hydroxy-5-methyl-4-isoxalon-propionic acid)-induced neuronal degeneration in the striatum of adult rats. The dose-dependent neurotoxic effect of AMPA was evaluated by the decrease in the activity of choline acetyltransferase (CHAT), due to degeneration of cholinergic neurons. An injection of 25 mg/kg GYKI 52466 30 min prior to the striatal application of 50 nmol AMPA, followed by repeated application of GYKI 52466 (10 times 5 mg/kg at 10 min intervals, reaching a final dose of 75 mg/kg) was able to prevent neuronal damage monitored by ChAT activity. Conversely, co-injection of GYKI 52466 (50 and 75 mg/kg) with AMPA (50 and 100 nmol) did not elicit any significant protection against the neuronal loss as measured by the ChAT enzyme activity. Therefore, one dose of agonist decreasing ChAT activity by about 40% (50 nmol) was tested on [3H]girisopam binding sites and on the immunoreactivity of glial fibrillary acid protein. The lesions were measured on methylene blue-stained serial sections with a computer assisted image analysis program (NIH Image 1.60). As a result of the AMPA treatment [3H]girisopam binding sites became depleted, and the immunoreactivity of glial fibrillary acid protein increased and on the site of the injection in the striatum a lesion developed. In the presence of AMPA (50 nmol) administered intrastriatally, GYKI 52466 (75 mg/kg i.p.) was able to make the radioactive signal of [3H]girisopam reappear. The volume of AMPA induced neuronal damage in the striatum and the extent of gliosis was reduced. These data provide evidence for the neuroprotective effect of GYKI 52466, and suggest a potential therapeutic value in some neurological disorders.

AB - The neuroprotective effect of intraperitonally administered GYKI 52466 (2,3-benzodiazepine derivate) was investigated on AMPA (alpha-amino-3- hydroxy-5-methyl-4-isoxalon-propionic acid)-induced neuronal degeneration in the striatum of adult rats. The dose-dependent neurotoxic effect of AMPA was evaluated by the decrease in the activity of choline acetyltransferase (CHAT), due to degeneration of cholinergic neurons. An injection of 25 mg/kg GYKI 52466 30 min prior to the striatal application of 50 nmol AMPA, followed by repeated application of GYKI 52466 (10 times 5 mg/kg at 10 min intervals, reaching a final dose of 75 mg/kg) was able to prevent neuronal damage monitored by ChAT activity. Conversely, co-injection of GYKI 52466 (50 and 75 mg/kg) with AMPA (50 and 100 nmol) did not elicit any significant protection against the neuronal loss as measured by the ChAT enzyme activity. Therefore, one dose of agonist decreasing ChAT activity by about 40% (50 nmol) was tested on [3H]girisopam binding sites and on the immunoreactivity of glial fibrillary acid protein. The lesions were measured on methylene blue-stained serial sections with a computer assisted image analysis program (NIH Image 1.60). As a result of the AMPA treatment [3H]girisopam binding sites became depleted, and the immunoreactivity of glial fibrillary acid protein increased and on the site of the injection in the striatum a lesion developed. In the presence of AMPA (50 nmol) administered intrastriatally, GYKI 52466 (75 mg/kg i.p.) was able to make the radioactive signal of [3H]girisopam reappear. The volume of AMPA induced neuronal damage in the striatum and the extent of gliosis was reduced. These data provide evidence for the neuroprotective effect of GYKI 52466, and suggest a potential therapeutic value in some neurological disorders.

KW - AMPA,

KW - ChAT

KW - Girisopam

KW - GYLI 52466

KW - Image analysis

KW - Neuroprotection

KW - Striatum

UR - http://www.scopus.com/inward/record.url?scp=0032461864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032461864&partnerID=8YFLogxK

M3 - Article

C2 - 9785349

AN - SCOPUS:0032461864

VL - 6

SP - 127

EP - 139

JO - Ideggyogyaszati Szemle

JF - Ideggyogyaszati Szemle

SN - 0019-1442

IS - 2

ER -